In vitro DNA binding studies of therapeutic and prophylactic drug Citral (cas 5392-40-5)
-
Add time:07/19/2019 Source:sciencedirect.com
The study of drug-DNA interactions is of great importance, as it paves the way towards the design of better therapeutic agents. Here, the interaction of DNA with a therapeutic and prophylactic drug citral has been studied. We have attempted to ascertain the mode of binding of citral with calf thymus DNA (Ct-DNA) through various biophysical techniques. Analysis of the UV–visible absorbance spectra and fluorescence spectra indicated the formation of a complex between citral and Ct-DNA. Competitive binding assays with ethidium bromide (EB), acridine orange (AO) and Hoechst 33258 reflected that citral possibly intercalates within the Ct-DNA. These observations were further confirmed by circular dichroism (CD) spectral analysis, viscosity measurements, DNA melting and molecular docking studies. This study is expected to contribute to a better understanding of molecular mechanisms of citral, and design of new drugs in the future.
We also recommend Trading Suppliers and Manufacturers of Citral (cas 5392-40-5). Pls Click Website Link as below: cas 5392-40-5 suppliers
Prev:Anti-inflammatory and anti-cancer activity of Citral (cas 5392-40-5): Optimization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer®
Next:Preparation and characterization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Vasorelaxant effect of the Lippia alba essential oil and its major constituent, Citral (cas 5392-40-5), on the contractility of isolated rat aorta07/22/2019
- Anti-hyperalgesic and anti-inflammatory effects of Citral (cas 5392-40-5) with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models07/20/2019
- Preparation and characterization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles07/21/2019
- Anti-inflammatory and anti-cancer activity of Citral (cas 5392-40-5): Optimization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer®07/18/2019
- Physiological response of Saccharomyces cerevisiae to Citral (cas 5392-40-5) combined with thermal treatment07/17/2019
- Antifungal activity and mechanism of Citral (cas 5392-40-5), limonene and eugenol against Zygosaccharomyces rouxii07/16/2019
- Effect of drying and interfacial membrane composition on the antimicrobial activity of emulsified Citral (cas 5392-40-5)07/15/2019